WALTHAM, MA -- January 30, 2007 -- PerkinElmer Inc. (NYSE: PKI), a global leader in Health Sciences and Photonics, today announced the introduction of its OneSource Laboratory Relocation service designed to handle the complex and time-consuming burdens laboratories face when moving equipment from one location to another. The service is available globally to facilitate the move of all laboratory equipment regardless of technology or manufacturer.

“OneSource can take care of every aspect of a relocation to enable scientists to keep their focus on the science,” said Dr. Joseph Tehrani, global business leader, Multi-vendor Validation and Relocation Solutions, PerkinElmer Life and Analytical Sciences.  “We take away the headaches – from pre-testing and inspection of equipment before a move through shipping, set-up and qualification testing.”  He added that the turnkey relocation service also encompasses preventive maintenance; moving of chemicals and samples; transportation; insurance; customs; and installation, qualification and commissioning at the new location.

“We streamline the process for customers – whether they’re a large pharmaceutical company or a small contract lab,” Tehrani added. “Customers have a single point of contact, a plan to minimize downtime, strong communication and realize increased efficiencies from PerkinElmer’s proven approach.”

“While any relocation is complex, organizations in heavily regulated environments, such as pharmaceutical companies, have the added need to document their process in a very deliberate fashion to ensure continued compliance,” Tehrani said.  “That’s no simple task, particularly when working with customized equipment from multiple vendors. Our experts remove this burden, enabling customers to focus on the pace and precision of their research and testing.” 

For more information about OneSource and its personalized relocation services, please send an e-mail to OneSource@perkinelmer.com.

Factors Affecting Future Performance
This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as “believes,” “intends,” “anticipates,” “plans,” “expects,” “projects,” “forecasts,” “will” and similar expressions, and references to guidance, are intended to identify forward-looking statements.  Such statements are based on management’s current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct.  A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements.  These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) our failure to protect adequately our intellectual property; (4) the loss of any of our licenses or licensed rights; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) our ability to produce an adequate quantity of products to meet our customers’ demands; (8) our failure to maintain compliance with applicable government regulations; (9) regulatory changes; (10) economic, political and other risks associated with foreign operations; (11) our ability to retain key personnel; (12) restrictions in our credit agreement; (13) our ability to realize the full value of our intangible assets; and (14) other factors which we describe under the caption “Risk Factors” in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

Other Information
Health Sciences end markets include genetic screening, environmental, service, biopharma, and medical imaging.  Photonics markets include sensors and specialty lighting.